Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu.

Schwaab, T; Lewis, L D; Cole, B F; Deo, Y; Fanger, M W; Wallace, P; Guyre, P M; Kaufman, P A; Heaney, J A; Schned, A R; Harris, R D; Ernstoff, M S

Schwaab, T; Lewis, L D; Cole, B F; Deo, Y; Fanger, M W; Wallace, P; Guyre, P M; Kaufman, P A; Heaney, J A; Schned, A R; Harris, R D; Ernstoff, M S.

Affiliation

Schwaab T; Uro-Oncology Program, Norris Cotton Cancer Center and Section of Urology and Immunology and Immunotherapy Research Programs, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.

J Immunother ; 24(1): 79-87, 2001.

Article in En | MEDLINE | ID: mdl-11211151

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Receptors, IgG / Receptor, ErbB-2 / Antibodies, Monoclonal Limits: Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: J Immunother Journal subject: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Year: 2001 Document type: Article Affiliation country:

Search on Google

Add to My VHL

XML

PubMed Links